Impella CP Implantation during Cardiopulmonary Resuscitation for Cardiac Arrest: A Multicenter Experience

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Vassili Panagides, Hopital Nord AP-HM, Mediterranean Association for Research and Studies in Cardiology, INSERM, Frankrig
  • ,
  • Henrik Vase
  • Sachin P Shah, Lahey Hospital and Medical Center, Burlington, MA.
  • ,
  • Mir B Basir, Henry Ford Hospital, Detroit, Michigan.
  • ,
  • Julien Mancini, Hôpital de la Timone, Marseille, France.
  • ,
  • Hayaan Kamran, Lahey Hospital and Medical Center, Burlington, MA.
  • ,
  • Supria Batra, Lahey Hospital and Medical Center, Burlington, MA.
  • ,
  • Marc Laine, Hopital Nord AP-HM, Mediterranean Association for Research and Studies in Cardiology, INSERM
  • ,
  • Hans Eiskjær
  • Steffen Christensen
  • Mina Karami, University of Amsterdam
  • ,
  • Franck Paganelli, Hopital Nord AP-HM, Mediterranean Association for Research and Studies in Cardiology, INSERM
  • ,
  • Jose P S Henriques, University of Amsterdam
  • ,
  • Laurent Bonello, Hopital Nord AP-HM, Mediterranean Association for Research and Studies in Cardiology, INSERM

BACKGROUND: Impella CP is a left ventricular pump which may serve as a circulatory support during cardiopulmonary resuscitation (CPR) for cardiac arrest (CA). Nevertheless, the survival rate and factors associated with survival in patients undergoing Impella insertion during CPR for CA are unknown.

METHODS: We performed a retrospective multicenter international registry of patients undergoing Impella insertion during on-going CPR for in- or out-of-hospital CA. We recorded immediate and 30-day survival with and without neurologic impairment using the cerebral performance category score and evaluated the factors associated with survival.

RESULTS: Thirty-five patients had an Impella CP implanted during CPR for CA. Refractory ventricular arrhythmias were the most frequent initial rhythm (65.7%). In total, 65.7% of patients immediately survived. At 30 days, 45.7% of patients were still alive. The 30-day survival rate without neurological impairment was 37.1%. In univariate analysis, survival was associated with both an age < 75 years and a time from arrest to CPR ≤ 5 min (p = 0.035 and p = 0.008, respectively).

CONCLUSIONS: In our multicenter registry, Impella CP insertion during ongoing CPR for CA was associated with a 37.1% rate of 30-day survival without neurological impairment. The factors associated with survival were a young age and a time from arrest to CPR ≤ 5 min.

OriginalsprogEngelsk
Artikelnummer339
TidsskriftJournal of Clinical Medicine
Vol/bind10
Nummer2
Antal sider10
ISSN2077-0383
DOI
StatusUdgivet - jan. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 209932934